dc.contributor.author | Çakırca, Mustafa | |
dc.contributor.author | Karatoprak, Cumali | |
dc.contributor.author | Zorlu, Mehmet | |
dc.contributor.author | Kıskaç, Muharrem | |
dc.contributor.author | Kanat, Mustafa | |
dc.contributor.author | Çıkrıkçıoğlu, Mehmet Ali | |
dc.contributor.author | Soysal, Pınar | |
dc.contributor.author | Hurşitoğlu, Mehmet | |
dc.contributor.author | Çamlı, Ahmet Adil | |
dc.contributor.author | Erkoç, Reha | |
dc.contributor.author | Abdul-Ghani, Muhammad | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T19:51:52Z | |
dc.date.available | 10.07.201910:49:13 | |
dc.date.available | 2019-07-10T19:51:52Z | |
dc.date.issued | 2014 | en_US |
dc.identifier.citation | Çakırca, M., Karatoprak, C., Zorlu, M., Kıskaç, M., Kanat, M., Çıkrıkçıoğlu, M.A. ... Abdul-Ghani, M. (2014). Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients. Drug Design, Development and Therapy, 8, 239-243. https://dx.doi.org/10.2147/DDDT.S52545 | en_US |
dc.identifier.issn | 1177-8881 | |
dc.identifier.uri | https://dx.doi.org/10.2147/DDDT.S52545 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/2299 | |
dc.description | WOS: 000331555100001 | en_US |
dc.description | PubMed ID: 24627624 | en_US |
dc.description.abstract | Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Materials and methods: A total of 68 type 2 DM patients who were on metformin were enrolled in the study. Based on the glycemic levels of patients, vildagliptin was added on to treatment in 33 patients. Patients were followed for 6 months. Serum ADMA, C-reactive protein, and fibrinogen levels were compared in groups of patients using metformin or metformin + vildagliptin, after 6 months. Results: Serum ADMA levels were found to be significantly lower in the group using vildagliptin compared to the group using metformin + vildagliptin (P<0.001). However, serum C-reactive protein and fibrinogen levels were statistically similar in the two study groups (P=0.34 and P=0.23, respectively). Conclusion: Metformin + vildagliptin treatment was observed to lower serum ADMA levels in type 2 DM patients. Our findings notwithstanding, large-scale prospective randomized controlled studies are warranted to conclude that vildagliptin provides cardiovascular protection along with diabetes regulation. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Dove Medical Press | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution-NonCommercial 3.0 Unported | * |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/3.0/ | * |
dc.subject | Asymmetric Dimethylarginine (ADMA) | en_US |
dc.subject | Dipeptidyl Peptidase-4 (DPP-4) Inhibitor | en_US |
dc.subject | Vildagliptin | en_US |
dc.subject | Type 2 Diabetes Mellitus | en_US |
dc.title | Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Drug Design, Development and Therapy | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.identifier.volume | 8 | en_US |
dc.identifier.startpage | 239 | en_US |
dc.identifier.endpage | 243 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.2147/DDDT.S52545 | en_US |
dc.identifier.wosquality | Q2 | en_US |
dc.identifier.scopusquality | Q1 | en_US |